You have Guest access.
Log In
Published in partnership with the
European Association for the Study of Diabetes
Commentary
M. Stumvoll and P. P. Nawroth
Journal Article
The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings
C. J. Currie
Diabetologia, 2009, Volume 52, Number 10, Pages 2234-2235
Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress
Subramanyam N. Murthy, Sergiy Sukhanov, Jennifer McGee, Joel A. Greco and Surabhi Chandra, et al.
Molecular and Cellular Biochemistry, 2009, Volume 330, Numbers 1-2, Pages 1-8
Insulin therapy in diabetes and cancer risk: Current understanding and implications for future study Proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK
Stephen C. L. Gough, Cristóbal Belda-Iniesta, Christopher Poole, Matthias Weber and David Russell-Jones, et al.
Advances in Therapy, 2011, Volume 28, Supplement 5, Pages 1-18
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study
J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle and J.-P. Hallé, et al.
Diabetologia, 2009, Volume 52, Number 9, Pages 1778-1788
Insufficient evaluation of adverse events is not a proof of safety
L. G. Hemkens, U. Grouven, R. Bender and P. T. Sawicki
Diabetologia, 2010, Volume 53, Number 4, Pages 790-792
Does diabetes therapy influence the risk of cancer?
U. Smith and E. A. M. Gale
Diabetologia, 2009, Volume 52, Number 9, Pages 1699-1708
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle and J. P. Hallé, et al.
Diabetologia, 2009, Volume 52, Number 9, Pages 1971-1973
Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial
Jean-Louis Selam and Luigi F. Meneghini
Advances in Therapy, 2009, Volume 26, Number 2, Pages 194-207
Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study
G. De Mattia, O. Laurenti and A. Moretti
Acta Diabetologica, 2009, Volume 46, Number 1, Pages 67-73
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter]
Diabetologia, 2009, Volume 52, Number 10, Pages 2236-2239
Keywords Cancer - Corporate governance - Diabetes - Insulin - Pharmaceutical industry
Frequently asked questions General info on journals and books Send us your feedback Impressum Contact us
© Springer, Part of Springer Science+Business Media Privacy, Disclaimer, Terms & Conditions, and Copyright Info